Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells.
Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells, according to a study in the latest journal of Cornea.
Dr X. Liu et al., Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, randomized 60 patients with dry eye into two groups.
Group 1 was administered topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%, while group 2 received sodium hyaluronate without pranoprofen. The outcome measures included ocular surface disease index (OSDI), tear film break-up time (TBUT), Schirmer I test results, ocular surface staining (OSS) results and conjunctival HLA-DR expression.
Group 1 demonstrated a significantly lower OSDI, OSS, and HLA-DR-positive cells, compared to group 2. However, TBUT was significantly longer in group 1 than group 2. On day 30 of the follow-up OSS differences between the group decreased in significance, but there were continued differences in OSDI, TBUT and HLA-DR expression between group 1 and 2.
On postoperative days 15 and 30 OSDI, TBUT and HLA-DR expression in group 1 demonstrated significant improvement, compared with results achieved in group 2. There were no significant effects in either group in the Schirmer test I values at days 15 and 30.
The abstract for this study can be found here.